SR-17018 and the 7-OH Detox Market: What the Research Actually Shows

As the DEA moves to schedule concentrated 7-OH and a wave of states ban it outright, a second-order market has appeared almost overnight: unregulated “research chemicals” sold as a way to self-detox from 7-OH and other opioids. The most talked-about of these is SR-17018 — sold online in bottles priced around $250 to $300, marketed to people desperate to get off 7-OH before it disappears from shelves.

For a full picture of what to expect, see current ibogaine treatment pricing.

For the practical playbook — withdrawal symptoms, a day-by-day timeline, and safe options — see our guide on how to detox from kratom and 7-OH.

The claims around SR-17018 have gotten dramatic. So it’s worth separating what the actual science shows from what the marketing says — because the gap between the two matters enormously if you’re the person considering spending $300 on a bottle to detox at home.

If you’re dependent on 7-OH or any opioid and trying to figure out a safe way through withdrawal, talk to someone first. Request a consultation or call (866) 435-7057.

Medical Disclaimer: SR-17018 is not an approved medication. It has never completed a human clinical trial. This article is educational reporting, not medical advice, and it is not an endorsement of SR-17018 or any research chemical. Opioid withdrawal can be dangerous. Do not attempt to self-treat withdrawal with an unregulated substance. Always work with a qualified medical provider.

What SR-17018 Actually Is

SR-17018 is an experimental compound first described in 2017 by researchers at Scripps Research, in a landmark paper led by Cullen Schmid in the journal Cell. It belongs to a class called G-protein-biased mu-opioid receptor agonists.

The idea behind biased agonism is elegant. Opioids like morphine activate two downstream pathways when they bind the mu receptor: the G-protein pathway (associated with pain relief) and the β-arrestin-2 pathway (associated with side effects like respiratory depression, tolerance, and dependence). SR-17018 was engineered to activate the G-protein pathway while largely avoiding β-arrestin recruitment — in the original screening it showed one of the highest “bias factors” ever measured, roughly 80 to 100 times more G-protein-selective than the reference compound.

In theory, a strongly biased agonist could provide pain relief with less of the tolerance, dependence, and breathing suppression that make conventional opioids dangerous. That theory is what makes SR-17018 scientifically interesting.

What the Research Actually Shows — and Where It Stops

Here is the finding that fuels the online claims. In a 2020 study published in Neuropsychopharmacology, Jenny Grim, Cullen Schmid, Laura Bohn, and colleagues reported that in mice, SR-17018 could reverse morphine tolerance while preventing morphine withdrawal. The researchers themselves noted the mechanism behind this effect was, at the time, unknown. Follow-up work confirmed SR-17018 did not produce analgesic tolerance in standard mouse assays the way morphine does.

That is a real, published, peer-reviewed result. It is also where the evidence stops, and the stopping point matters:

• Every one of these findings is from animal studies. SR-17018 has never completed a human clinical trial. There is no published data on whether it prevents withdrawal in people, at what dose, or with what safety profile.
• It is not approved for any use, anywhere in the world. No FDA approval, no investigational-new-drug authorization for treating people.
• The same body of research shows a catch the marketing leaves out. Animal studies indicate SR-17018 can itself produce physical dependence and withdrawal after repeated exposure. It is still an opioid acting on the same receptor as morphine. “Biased” does not mean “non-addictive.”

So the honest summary is this: SR-17018 is a genuinely intriguing research compound with promising animal data on tolerance and withdrawal, and effectively zero human data on safety or effectiveness. Anyone telling you it “completely eliminates” withdrawal in people is describing a hope, not a finding.

The Market That Appeared With the 7-OH Ban

The regulatory pressure on 7-OH created a vacuum, and an unregulated market moved to fill it. SR-17018 is now sold as a “research chemical” — typically as a powder or a solution in bottles priced around $250 to $300 — and increasingly marketed, directly or by implication, as a way to detox off 7-OH and other opioids at home.

Anecdotal reports from users on forums like Bluelight and Reddit are genuinely mixed. Some people describe SR-17018 easing their step-down off opioids or kratom. Others describe it doing little, or describe developing dependence on SR-17018 itself. These reports are anecdotal and unverified. They are not clinical evidence, they are not dosed or measured under controlled conditions, and there is no way to confirm what any given user actually took — which is the core problem with the entire category.

A few realities worth stating plainly about buying an unapproved opioid online to self-detox:

• You cannot verify purity or contents. “Research-grade” is a marketing phrase, not a regulatory standard. There is no oversight of what is actually in the bottle.
• There are no established human dosing guidelines — because there are no human trials.
• You would be managing opioid withdrawal alone, without the monitoring that makes withdrawal safer, and while introducing a second opioid that can create its own dependence.
• The respiratory-safety advantage seen in mice has never been confirmed in humans.

None of this is a moral judgment. The impulse is completely understandable: people who became dependent on a product sold as a harmless supplement are now facing withdrawal and a treatment system that isn’t ready for them. Paying $300 for a bottle that promises a way out is a rational act of desperation. But desperation is exactly the condition under which unregulated products cause harm.

The Safer Path Runs Through Supervision

The reason 7-OH became a problem in the first place is that it was an opioid sold without medical oversight. Detoxing with another unapproved opioid, also without oversight, repeats the pattern that caused the harm.

The evidence-based options for opioid dependence — including dependence on 7-OH — all involve medical supervision:

• Medication-assisted treatment (MAT). Buprenorphine and methadone are the standard of care, legal, and available now. For many people stepping off 7-OH, a supervised buprenorphine taper is the most direct and safest route.
• Medically supervised detox and rehabilitation.
• Ibogaine. For patients who have cycled through conventional treatment without lasting results, ibogaine stands in sharp contrast to SR-17018 on the one dimension that matters most: it has human evidence. Ibogaine has been observed to interrupt opioid withdrawal and craving across opioid classes, received FDA Breakthrough Therapy Designation, and was the subject of a 2024 Stanford study documenting significant improvements in veterans. It is a Schedule I substance in the U.S., so it is administered at licensed clinics abroad — under medical supervision, with mandatory cardiac screening, because ibogaine itself carries real cardiac risk. Our Ibogaine Safety Guide covers that screening in detail.

The common thread is supervision. The difference between a treatment and a gamble is whether a qualified person is monitoring what happens.

How Psychedelic Connect Can Help

Psychedelic Connect is a patient advisory service. If you’re dependent on 7-OH or another opioid and trying to sort through the noise — including the noise around research chemicals like SR-17018 — we can help you understand the real options, and connect you with vetted, medically supervised clinics if that’s the right path for you.

We don’t sell anything, we don’t recommend research chemicals, and we don’t take payment from patients. Request your consultation or call (866) 435-7057. If you’re in immediate crisis, contact the SAMHSA National Helpline at 1-800-662-HELP (4357) or call 988.

Frequently Asked Questions

Q: Does SR-17018 stop opioid and 7-OH withdrawal? In mouse studies, SR-17018 reversed morphine tolerance and prevented morphine withdrawal (Grim et al., Neuropsychopharmacology, 2020). There are no human clinical trials, so there is no verified evidence that it stops withdrawal safely or effectively in people. Claims that it “completely eliminates” withdrawal in humans are not supported by evidence.

Q: Is SR-17018 FDA approved? No. SR-17018 is not approved for any medical use anywhere in the world and has never completed a human clinical trial. It is sold as an unregulated “research chemical.”

Q: Is SR-17018 addictive? It is an opioid that acts on the mu-opioid receptor. Animal research indicates it can produce physical dependence and withdrawal with repeated use. “G-protein biased” does not mean non-addictive.

Q: Why is SR-17018 being sold as a 7-OH detox? As 7-OH faces federal scheduling and state bans, an unregulated market emerged selling SR-17018 — often around $250–$300 a bottle — marketed as a way to self-detox. This is a market response to a treatment gap, not a validated medical protocol.

Q: What’s a safer way to detox from 7-OH? Talk to a medical provider. Evidence-based options include a supervised buprenorphine taper, medically supervised detox, and — for some patients — ibogaine, which unlike SR-17018 has human evidence and is administered under medical supervision. Do not attempt to self-treat opioid withdrawal with an unregulated substance.

Q: Is pharma hiding SR-17018? No. SR-17018 came out of academic research at Scripps and its findings are openly published in journals including Cell and Neuropsychopharmacology. The reason it isn’t available as a medicine is that it has not been through human clinical trials to establish that it is safe and effective in people — the same bar every approved medication must clear.